This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Rare Disease Innovation & Partnership Summit
March 21-23, 2023
Delivered as a Hybrid EventPhiladelphia Marriott Downtown

Ana Puhl
Associate Director at Collaborations Pharmaceuticals Inc.


I am Associate Director at Collaborations Pharmaceuticals. I joined the company in 2018 and am involved in drug discovery projects for rare genetic and neglected diseases. I am passionate about drug discovery and committed to finding solutions to improve people’s lives.

My background is in protein crystallography, where I did a PhD at the University of Sao Paulo, Brazil, followed by Post-Doctoral studies at GlaxoSmithKline (USA) and the University of North Carolina (USA). Currently, at Collaborations Pharmaceuticals, I am focused on developing an enzyme replacement therapy for CLN1 Batten Disease.

Agenda Sessions

  • Developing Treatments for Rare Diseases on a Shoestring—The Batten Disease CLN1 Experience